IMMP · Immutep's Q1 FY27 quarterly activities report shows continued progress…

Immutep's Q1 FY27 quarterly activities report shows continued progress in the root cause analysis of the TACTI-004 Phase III failure, with structural differences identified between the 2000L and 200L scale efti batches. The company has contracted a new 200L scale manufacturing run and intends to focus registration-directed development of efti on HNSCC (CPS<1) and neoadjuvant STS, with study start targeted for H2 CY27. Cash and term deposits stand at A$48.50 million, with runway extending well into H1 CY28, while net operating cash outflow improved to A$19.1 million from A$38.9 million in Q4 FY26.

• Cash and term deposits of A$48.50 million at 30 September 2026, with cash runway expected to extend well into H1 CY28
• Net cash used in operating activities was A$19.1 million in Q1 FY27, down from A$38.9 million in Q4 FY26
• Root cause analysis of TACTI-004 identified structural differences between 2000L scale efti used in the trial and 200L scale efti used in earlier successful studies
• New manufacturing run of efti at 200L scale has been contracted